Objective To explore the changes of systemic immune-inflammation index (SII), fibrosis 4 (FIB-4) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), and their relationship with prognosis of patients with dilated cardiomyopathy (DCM) and heart failure with reduced ejection fraction (HFrEF). Methods A retrospective analysis was performed on the clinical data of 115 patients with DCM and HFrEF (disease group) and 100 healthy controls (healthy group) in the hospital between May 2022 and April 2024. The levels of SII, FIB-4 and NT-proBNP were compared between the two groups. The patients in disease group were followed up for 6 months. According to presence or absence of adverse cardiovascular events, they were divided into good prognosis group (n=63) and poor prognosis group (n=52). The relationship between changes of SII, FIB-4 and NT-proBNP and prognosis was analyzed. Results The levels of SII, FIB-4 and NT-proBNP in disease group were higher than those in healthy group. There were significant differences in levels of SII, FIB-4 and NT-proBNP among different cardiac function grading groups, and which were the highest in grade IV group. The proportion of grade IV cardiac function, levels of SII, FIB-4 and NT-proBNP in poor prognosis group were higher than those in good prognosis group. ROC curves analysis showed that AUC values of SII, FIB-4, NT-proBNP and combined detection were 0.814, 0.779, 0.848 and 0.862, respectively, showing certain predictive value for poor prognosis. The sensitivity of combined detection was higher. Multivariate Logistic regression analysis showed that grade IV cardiac function, SII ≥413.485, FIB-4 ≥3.876 and NT-proBNP ≥4263.98pg/mL were risk factors of poor prognosis in patients with DCM and HFrEF. Conclusion The expressions of SII, FIB-4 and NT-proBNP are up-regulated in patients with DCM and HFrEF, which are risk factors of poor prognosis. The three indexes all have certain predictive value for prognosis.
Key words
dilated cardiomyopathy /
heart failure with reduced ejection fraction /
systemic immune-inflammation index /
fibrosis 4 /
N-terminal pro-B-type natriuretic peptide
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] HEYMANS S, LAKDAWALA NK, TSCHÖPE C, et al. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches[J]. Lancet, 2023, 402(10406): 998-1011.
[2] ORPHANOU N, PAPATHEODOROU E, ANASTASAKIS A.Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments[J]. Heart Fail Rev, 2022, 27(4): 1173-1191.
[3] CAVUSOGLU Y, TAHMAZOV S, MURAT S, et al.Immunoadsorption therapy in refractory heart failure patients with dilated cardiomyopathy: a potential therapeutic option[J]. Rev Assoc Med Bras, 2023, 69(1): 90-96.
[4] 田志广. 黄芪保心汤联合曲美他嗪治疗扩张型心肌病心衰临床观察[J]. 实用中医药杂志, 2024, 40(8): 1543-1545.
[5] 刘加宝, 张艳娟, 王连生, 等. 维立西呱联合“新四联”药物对扩张型心肌病心衰患者的治疗效果分析[J]. 南京医科大学学报(自然科学版), 2024, 44(12): 1682-1689.
[6] 蔡美莲, 钟国强. 盐酸奥普力农注射液联合注射用重组人脑利钠肽治疗扩张型心肌病所致急性心力衰竭效果观察[J]. 山东医药, 2023, 63(31): 72-74.
[7] BOZKURT B, COATS A, TSUTSUI H, et al.Universal definition and classification of heart failure[J]. Eur J Heart Fail, 2021, 23(3): 352-380.
[8] 闵轩, 王凯阳, 宁怡, 等. 系统免疫炎症指数与冠心病患者冠状动脉病变程度的相关性研究[J]. 中国心血管杂志, 2023, 28(3): 228-233.
[9] 聂流畅, 李秀芩, 李绍冰. 肝纤维化-4指数评价心力衰竭预后价值的Meta分析[J]. 中国循环杂志, 2022, 37(9): 902-906.
[10] 中华医学会心血管病学分会, 中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志, 2018, 34(5): 421-434.
[11] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789.
[12] SINAGRA G, GIGLI M, DAL FERRO M.Heart failure with reduced ejection fraction and monogenic dilated cardiomyopathy: distinct diseases? insights from randomized controlled trials[J]. Eur J Heart Fail, 2023, 25(8): 1267-1269.
[13] 沈盛晖, 叶建华, 徐长福, 等. 温阳益气活血汤联合依那普利治疗扩张型心肌病的临床观察[J]. 中国中医药科技, 2020, 27(2): 280-282.
[14] ZHANG J, CHENG L, LI Z, et al.Immune cells and related cytokines in dilated cardiomyopathy[J]. Biomed Pharmacother, 2024, 171: 116159.
[15] 扎西卓玛, 王吴婉, 林雪. 扩张型心肌病伴心力衰竭患者出院后死亡的影响因素分析[J]. 中国心血管杂志, 2022, 27(2): 123-128.
[16] LAZAR-POLOCZEK E, ROMUK E, JACHEĆ W, et al.Association of NT-proBNP and sST2 with left ventricular ejection fraction and oxidative stress in patients with stable dilated cardiomyopathy[J]. Biomedicines, 2024, 12(4): 707.
[17] 白杨, 姜伟鹏, 夏成蕴, 等. 血清NT-proBNP、HE4、β2-MG、sST2与扩张型心肌病患者心室重构的关系及对出院后短期预后的预测价值[J]. 现代生物医学进展, 2022, 22(17): 3259-3263, 3274.
[18] 中国医师协会检验医师分会心血管专家委员会. B型利钠肽及N末端B型利钠肽前体实验室检测与临床应用中国专家共识[J]. 中华医学杂志, 2022, 102(35): 2738-2754.
[19] HARDING D, CHONG MHA, LAHOTI N, et al.Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy[J]. J Intern Med, 2023, 293(1): 23-47.
[20] 邵梦娇, 石佳, 王欢. 系统免疫炎症指数对扩张型心肌病合并射血分数降低的心力衰竭患者左心室逆重构的预测价值[J]. 中国循环杂志, 2024, 39(7): 695-702.
[21] ASPROMONTE N, FUMARULO I, PETRUCCI L, et al.The liver in heart failure: from biomarkers to clinical risk[J]. Int J Mol Sci, 2023, 24(21): 15665.
[22] 张丽伟, 李晓丹, 赵赫, 等. 射血分数正常心力衰竭患者Fibrosis-4指数与右心室功能及预后的相关性研究[J]. 现代检验医学杂志, 2022, 37(2): 167-172.
[23] 陶学娇, 卢均坤, 陈嘉辉, 等. FIB-4、sST2水平与心力衰竭及其严重程度的相关性分析[J]. 新医学, 2023, 54(8): 569-573.
PDF(2942 KB)
